Universal influenza virus vaccines: need for clinical trials

To overcome the limitations of seasonal influenza virus vaccines and enhance our pandemic preparedness, influenza virus vaccines that provide universal and long-lasting protection are needed.

[1]  A. Osterhaus,et al.  Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine‐induced antibody response to this strain in the elderly , 2000, Journal of medical virology.

[2]  P. Heinen,et al.  Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. , 2002, The Journal of general virology.

[3]  James E. Crowe,et al.  Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors , 2008, Nature.

[4]  A. Vincent,et al.  Failure of protection and enhanced pneumonia with a US H1N2 swine influenza virus in pigs vaccinated with an inactivated classical swine H1N1 vaccine. , 2008, Veterinary microbiology.

[5]  Patrick C. Wilson,et al.  Rapid cloning of high-affinity human monoclonal antibodies against influenza virus , 2008, Nature.

[6]  Gira Bhabha,et al.  Antibody Recognition of a Highly Conserved Influenza Virus Epitope , 2009, Science.

[7]  Eduardo Lazcano-Ponce,et al.  Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study in Mexico City , 2009, BMJ : British Medical Journal.

[8]  Boguslaw Stec,et al.  Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses , 2009, Nature Structural &Molecular Biology.

[9]  Laura C. Rosella,et al.  Association between the 2008–09 Seasonal Influenza Vaccine and Pandemic H1N1 Illness during Spring–Summer 2009: Four Observational Studies from Canada , 2010, PLoS medicine.

[10]  G. Nabel,et al.  Induction of Broadly Neutralizing H1N1 Influenza Antibodies by Vaccination , 2010, Science.

[11]  Christopher L. Perdue,et al.  Seasonal Influenza Vaccine and Protection against Pandemic (H1N1) 2009-Associated Illness among US Military Personnel , 2010, PloS one.

[12]  Martin H. Koldijk,et al.  A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses , 2011, Science.

[13]  F. Ennis,et al.  Complement-Dependent Lysis of Influenza A Virus-Infected Cells by Broadly Cross-Reactive Human Monoclonal Antibodies , 2011, Journal of Virology.

[14]  J. Skehel,et al.  A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins , 2011, Science.

[15]  P. Palese,et al.  Why Do Influenza Virus Subtypes Die Out? A Hypothesis , 2011, mBio.

[16]  N. S. Laursen,et al.  Highly Conserved Protective Epitopes on Influenza B Viruses , 2012, Science.

[17]  Adolfo García-Sastre,et al.  Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses , 2012, Proceedings of the National Academy of Sciences.

[18]  J. Whittle,et al.  Elicitation of Broadly Neutralizing Influenza Antibodies in Animals with Previous Influenza Exposure , 2012, Science Translational Medicine.

[19]  J. Wong,et al.  Protective efficacy against pandemic influenza of seasonal influenza vaccination in children in Hong Kong: a randomized controlled trial. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  P. V. Van Caeseele,et al.  No Association between 2008–09 Influenza Vaccine and Influenza A(H1N1)pdm09 Virus Infection, Manitoba, Canada, 2009 , 2012, Emerging infectious diseases.

[21]  Tao Dong,et al.  Preliminary Assessment of the Efficacy of a T-Cell–Based Influenza Vaccine, MVA-NP+M1, in Humans , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  R. Hai,et al.  Hemagglutinin Stalk-Reactive Antibodies Are Boosted following Sequential Infection with Seasonal and Pandemic H1N1 Influenza Virus in Mice , 2012, Journal of Virology.

[23]  G. Air,et al.  Evaluations for In Vitro Correlates of Immunogenicity of Inactivated Influenza A H5, H7 and H9 Vaccines in Humans , 2012, PloS one.

[24]  Jie Dong,et al.  Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus. , 2018 .

[25]  J. Whittle,et al.  Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies , 2013, Nature.

[26]  Matthew S. Miller,et al.  1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans. , 2013, The Journal of infectious diseases.

[27]  N. Heaton,et al.  Hemagglutinin Stalk-Based Universal Vaccine Constructs Protect against Group 2 Influenza A Viruses , 2013, Journal of Virology.

[28]  A. Vincent,et al.  Vaccine-Induced Anti-HA2 Antibodies Promote Virus Fusion and Enhance Influenza Virus Respiratory Disease , 2013, Science Translational Medicine.

[29]  R. Hai,et al.  Chimeric Hemagglutinin Influenza Virus Vaccine Constructs Elicit Broadly Protective Stalk-Specific Antibodies , 2013, Journal of Virology.

[30]  John J. Treanor,et al.  H3N2 Influenza Virus Infection Induces Broadly Reactive Hemagglutinin Stalk Antibodies in Humans and Mice , 2013, Journal of Virology.